Literature DB >> 17362670

Painful lessons: COX-2 inhibitors, NSAIDs, and hypertension.

Frank Ruschitzka1.   

Abstract

Entities:  

Year:  2007        PMID: 17362670     DOI: 10.1007/s11906-007-0008-4

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   4.592


× No keyword cloud information.
  19 in total

1.  Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.

Authors:  Scott D Solomon; Marc A Pfeffer; John J V McMurray; Rob Fowler; Peter Finn; Bernard Levin; Craig Eagle; Ernest Hawk; Mariajosé Lechuga; Ann G Zauber; Monica M Bertagnolli; Nadir Arber; Janet Wittes
Journal:  Circulation       Date:  2006-09-05       Impact factor: 29.690

2.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

Authors:  Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

3.  Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation.

Authors:  Jan Steffel; Matthias Hermann; Helen Greutert; Steffen Gay; Thomas F Lüscher; Frank Ruschitzka; Felix C Tanner
Journal:  Circulation       Date:  2005-03-28       Impact factor: 29.690

4.  The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.

Authors:  James R Sowers; William B White; Bertram Pitt; Andrew Whelton; Lee S Simon; Nathaniel Winer; Alan Kivitz; Hein van Ingen; Thomas Brabant; John G Fort
Journal:  Arch Intern Med       Date:  2005-01-24

5.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors:  F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

6.  Non-narcotic analgesic dose and risk of incident hypertension in US women.

Authors:  John P Forman; Meir J Stampfer; Gary C Curhan
Journal:  Hypertension       Date:  2005-08-15       Impact factor: 10.190

7.  Selective COX-2 inhibition improves endothelial function in coronary artery disease.

Authors:  Rémy Chenevard; David Hürlimann; Markus Béchir; Frank Enseleit; Lukas Spieker; Matthias Hermann; Walter Riesen; Steffen Gay; Renate E Gay; Michel Neidhart; Beat Michel; Thomas F Lüscher; Georg Noll; Frank Ruschitzka
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

8.  Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study.

Authors:  Muhammad Mamdani; David N Juurlink; Douglas S Lee; Paula A Rochon; Alex Kopp; Gary Naglie; Peter C Austin; Andreas Laupacis; Therese A Stukel
Journal:  Lancet       Date:  2004-05-29       Impact factor: 79.321

9.  Relationship between COX-2 specific inhibitors and hypertension.

Authors:  Daniel H Solomon; Sebastian Schneeweiss; Raisa Levin; Jerry Avorn
Journal:  Hypertension       Date:  2004-06-28       Impact factor: 10.190

10.  Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization?

Authors:  Steven A Grover; Louis Coupal; Hanna Zowall
Journal:  Hypertension       Date:  2004-11-15       Impact factor: 10.190

View more
  1 in total

Review 1.  Clinical use and pharmacological properties of selective COX-2 inhibitors.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2007-11-13       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.